What is it? Why is it important?

The Site-Investigator (Site-INV) is responsible to ensure the safety of study participant and the quality of study data at a particular study site.

 

During study conduct the Site-INV must:

 

 

The Site-INV can delegate tasks and QMS responsibilities to study staff. Still, the ultimate responsibility remains with the Site-INV, who ensures the qualification and training of study staff.

What do I need to do?

As a Site-INV familiarise yourself and comply with:

  • The study protocol and the Quality by Design (QbyD) approach defined by the SP-INV (e.g. from set-up to completion)
  • Regulatory requirements (e.g. Swiss law) and applicable guidelines (e.g. ICH GCP, ISO 14155)
  • Defined risk-management procedures (e.g. risk documentation and review procedures)
  • Timely and correct filing of study documents (e.g. ISF)
  • Maintain ongoing study oversight, with oversight levels proportionate to the criticality of delegated activities (e.g. risks to Critical to Quality (CtoQ) factors, such as safety of study participant and quality of study data)
  • Ensure that data acquisition tools and electronic systems deployed at the site are used as specified, maintaining participant privacy and data security requirements

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 2.3 responsibilities
  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management

Documents

Abbreviations
  • CtoQ - critical-to-quality
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ICH - International Council for Harmonisation
  • ISF – Investigator Site File
  • ISO – International Organization for Standardization
  • QbyD – Quality by Design
  • Site-INV – Site-Investigator
  • SOP – Standard Operating Procedures
  • Site-INV – Site Investigator
  • SP-INV – Sponsor-Investigator
  • WI – Working Instructions
Basic ↦ Quality and Risk ↦ Quality Responsibilities ↦ Site-Investigator
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Quality Responsibilities ↦ Site-Investigator